GB2477768A - Pharmaceutical material for treating psoriasis - Google Patents

Pharmaceutical material for treating psoriasis Download PDF

Info

Publication number
GB2477768A
GB2477768A GB1002365A GB201002365A GB2477768A GB 2477768 A GB2477768 A GB 2477768A GB 1002365 A GB1002365 A GB 1002365A GB 201002365 A GB201002365 A GB 201002365A GB 2477768 A GB2477768 A GB 2477768A
Authority
GB
United Kingdom
Prior art keywords
preparation
weight
pharmaceutical material
psoriasis
artemisia capillaris
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1002365A
Other versions
GB201002365D0 (en
Inventor
Chao-Ho Liu
Meng-Han Liu
jia-ying Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB1002365A priority Critical patent/GB2477768A/en
Publication of GB201002365D0 publication Critical patent/GB201002365D0/en
Publication of GB2477768A publication Critical patent/GB2477768A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Abstract

A pharmaceutical material for use in treating psoriasis includes a liquid preparation by extracting herbs selected from the group consisting of Artemisia capillaris, Plumeria acutifolia, and Melaleuca alternifolia. Artemisia capillaris may comprise about 5 to about 21 weight % of the preparation, Plumeria acutifolia may comprise about 65 to about 90 weight % of the preparation, and Melaleuca alternifolia may comprise about 4 to about 16 weight % of the preparation respectively. Alternatively, the pharmaceutical material for use in the treatment of psoriasis may comprise a dust-like preparation by powdering herbs selected from the group consisting of Artemisia capillaris, Plumeria acutifolia, and Melaleuca alternifolia.

Description

PHARMACEUTICAL MATERIAL FOR PSORIASIS TREATMENT
BACKGROUND OF THE INVENTION
1. Field of Invention
The invention relates to the treatment of psoriasis and more particularly to an improved pharmaceutical material prepared from herbs for the treatment of psoriasis.
2. Description of Related Art
Psoriasis is a chronic, non-contagious disease that affects mainly the skin. It typically causes red, scaly patches to appear on the skin. The scaly patches caused by psoriasis, called psoriatic plaques, are areas of inflammation and excessive skin production. Fingernails and toenails are frequently affected.
Treatments of psoriasis are well known. For example, U.S. Pat. No. 4,826,677 discloses a pharmaceutical material for topical treating of psoriasis. The disadvantages of some topical agents include, but not limited to, normal skin irritation, time consuming, and being not suitable for use for long periods of time. Thus, continuing improvements in the exploitation of pharmaceutical material for psoriasis treatment are constantly being sought.
SUMMARY OF THE INVENTION
It is therefore one object of the invention to provide a pharmaceutical material for treating of psoriasis comprising a liquid preparation by extracting herbs selected from the group consisting of Artemisia capillaris, Plumeria acutifolia, and Melaleuca altern ifol ia.
It is another object of the invention to provide a pharmaceutical material for treating of psoriasis comprising a dustlike preparation by powdering herbs selected from the group consisting of Artemisia capillaris, Plumeria acutifolia, and Melaleuca alternifolia.
In one aspect of the invention Artemisia capillaris is about 5 to about 21 weight % of the preparation, Plumeria acutifolia is about 65 to about 90 weight % of the preparation, and Melaleuca alternifolia is about 4 to about 16 weight % of the preparation respectively.
DETAILED DESCRIPTION OF THE INVENTION
A pharmaceutical material for psoriasis treatment in accordance with a first preferred embodiment of the invention comprises a liquid preparation by extracting herbs selected from the group consisting of Artemisia capillaris, Plumeria acutifolia, and Melaleuca alternifolia.
Preferably, Artemisia capillaris is about 5 to about 21 weight % of the preparation, Plumeria acutifolia is about 65 to about 90 weight % of the preparation, and Melaleuca alternifolia is about 4 to about 16 weight % of the preparation respectively.
A pharmaceutical material for psoriasis treatment in accordance with a second preferred embodiment of the invention comprises a dustlike preparation by powdering herbs selected from the group consisting of Artemisia capillaris, Plumeria acutifolia, and Melaleuca alternifolia.
Preferably, Artemisia capillaris is about 5 to about 21 weight % of the preparation, Plumeria acutifolia is about 65 to about 90 weight % of the preparation, and Melaleuca alternifolia is about 4 to about 16 weight % of the preparation respectively.
In each of the first and second preferred embodiments, the preparation can be applied to the skin.
In each of the first and second preferred embodiments, the preparation can be produced in the form of, in addition to above liquid and dustlike form, ointment, adhering film, solution, moisturizer, jelly, cream, lotion, bath oil, etc. While the invention herein disclosed has been described by means of specific embodiments, numerous modifications and variations could be made thereto by those skilled in the art without departing from the scope and spirit of the invention set forth in the claims.

Claims (4)

  1. WHAT IS CLAIMED IS: 1. A pharmaceutical material for treating of psoriasis comprising a liquid preparation by extracting herbs selected from the group consisting of Artemisia capillaris, Plumeria acutifolia, and Melaleuca alternifolia.
  2. 2. The pharmaceutical material of claim 1, wherein Artemisia capillaris is about 5 to about 21 weight % of the preparation, Plumeria acutifolia is about 65 to about 90 weight % of the preparation, and Melaleuca alternifolia is about 4 to about 16 weight % of the preparation respectively.
  3. 3. A pharmaceutical material for treating of psoriasis comprising a dustlike preparation by powdering herbs selected from the group consisting of Artemisia capillaris, Plumeria acutifolia, and Melaleuca alternifolia.
  4. 4. The pharmaceutical material of claim 3, wherein Artemisia capillaris is about 5 to about 21 weight % of the preparation, Plumeria acutifolia is about 65 to about 90 weight % of the preparation, and Melaleuca alternifolia is about 4 to about 16 weight % of the preparation respectively.
GB1002365A 2010-02-12 2010-02-12 Pharmaceutical material for treating psoriasis Withdrawn GB2477768A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1002365A GB2477768A (en) 2010-02-12 2010-02-12 Pharmaceutical material for treating psoriasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1002365A GB2477768A (en) 2010-02-12 2010-02-12 Pharmaceutical material for treating psoriasis

Publications (2)

Publication Number Publication Date
GB201002365D0 GB201002365D0 (en) 2010-03-31
GB2477768A true GB2477768A (en) 2011-08-17

Family

ID=42110606

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1002365A Withdrawn GB2477768A (en) 2010-02-12 2010-02-12 Pharmaceutical material for treating psoriasis

Country Status (1)

Country Link
GB (1) GB2477768A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750108A (en) * 1995-09-18 1998-05-12 Regenix Marketing Systems, Inc. Hair treatment system and kit for invigorating hair growth
JPH10291926A (en) * 1997-04-21 1998-11-04 Shiseido Co Ltd Protease inhibitor
US20020176876A1 (en) * 2001-01-23 2002-11-28 Harris Dennis H. Topical therapeutic skin care system
EP1958613A1 (en) * 2007-02-15 2008-08-20 Polichem S.A. Dermal film-forming liquid formulations for drug release to skin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750108A (en) * 1995-09-18 1998-05-12 Regenix Marketing Systems, Inc. Hair treatment system and kit for invigorating hair growth
JPH10291926A (en) * 1997-04-21 1998-11-04 Shiseido Co Ltd Protease inhibitor
US20020176876A1 (en) * 2001-01-23 2002-11-28 Harris Dennis H. Topical therapeutic skin care system
EP1958613A1 (en) * 2007-02-15 2008-08-20 Polichem S.A. Dermal film-forming liquid formulations for drug release to skin

Also Published As

Publication number Publication date
GB201002365D0 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
WO2010070675A3 (en) Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
WO2014140861A3 (en) Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
RU2012113101A (en) COMPOSITION FOR EXTERNAL USE ON SKIN CONTAINING SALT AND SUGAR AS ACTIVE INGREDIENTS FOR THE PREVENTION AND TREATMENT OF VAGINOSIS AND ITS APPLICATION
Mousavi et al. A clinical study of efficacy of garlic extract versus cryotherapy in the treatment of male genital wart
Ali et al. Flavonoids from Blumea balsamifera
US20110171326A1 (en) Pharmaceutical material for psoriasis treatment
WO2012140013A3 (en) Use of compositions for the treatment of inflammatory skin conditions, scaly scalp conditions
US20190060220A1 (en) Process and Method to Accelerate Cellular Regeneration, Healing and Wound Management
GB2477768A (en) Pharmaceutical material for treating psoriasis
WO2007082864A3 (en) Use of chavicol as an antiseptic
Coopoosamy et al. A comparative study of three Aloe species used to treat skin diseases in South African rural communities
Althaf Faimum et al. In Vitro anti-inflammatory activity of Vitex leucoxylon Linn. leaves by HRBC membrane stabilization.
MX2016007973A (en) Topical composition comprising natural ingredients for bruising or hematoma healing on skin and use thereof.
CN106727208A (en) Lipstick
WO2016114621A3 (en) Composition for prevention or treatment of metabolic bone diseases comprising combined extract of schisandra chinesis, eucommiae cortex and lycium chinense as active ingredient
CN105616239A (en) Sun-screening and moisturizing gel
CN104490736A (en) Aloe cream capable of removing freckle, whitening and beautifying
CN103933206A (en) Medicament lotion for treating skin itch of old people
Zohreh et al. Medicinal herbs effective on the skin
WO2012083397A8 (en) Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis
Ghaffari et al. The chamomile in islamic and iranian traditional medicine context
ATE546137T1 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING WARTS
Narkhede et al. Anti-inflammatory activity of Vetiveria zizanioides (Linn.) root
CN106902133A (en) One kind treats dermopathic medicine
CN104352785A (en) Concentrated solution used for preventing and treating eczema, seborrheic dermatitis and acne

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)